Lifeboat Foundation

Results of a recently completed clinical trial of a potential drug to treat Type 2 diabetes in children were announced Sunday [April 28] at the Pediatric Academic Societies 2019 meeting in Baltimore, Md. The New England Journal of Medicine also published the findings. Study coauthor Jane Lynch, M.D., FAAP, professor of pediatrics at UT Health San Antonio, said the drug, liraglutide, in combination with an existing medication, metformin, showed robust effect in treating children studied in the Ellipse trial.

Currently only two drugs, metformin and insulin, are approved by the U.S. Food and Drug Administration for the treatment of Type 2 diabetes in children. By comparison, more than 30 drugs are approved to treat this form of diabetes in adults.

“We’ve not been able to get drugs approved for children beyond metformin and insulin,” Dr. Lynch said. “This adult diabetes medication was very effective in our trial of youth with Type 2 diabetes and was well tolerated. We urgently need other options for medical treatment of Type 2 diabetes in our youth under age 18. If approved, this drug would be a fantastic new option to complement oral metformin therapy as an alternative to insulin for our youth and adolescents with Type 2 diabetes.”

Continue reading “Finally, another effective drug for kids and teens with type 2 diabetes” »

Researchers from University of Jyväskylä and Aalto University in Finland have developed a customized DNA nanostructure that can perform a predefined task in human body-like conditions. To do so, the team built a capsule-like carrier that opens and closes according to the pH level of the surrounding solution. The nanocapsule can be loaded—or packed—with a variety of cargo, closed for delivery and opened again through a subtle pH increase.

The findings, published in the journal Nature Medicine, showcase a novel CRISPR/Cas9 genome-editing therapy that can suppress the accelerated aging observed in mice with Hutchinson-Gilford progeria syndrome. This treatment provides an important insight into the molecular pathways involved in accelerated aging, as well as how to reduce toxic proteins via gene therapy. The researchers hope to translate this therapy to humans to potentially provide a cure for progeria as well as possibly slowing down the aging process to delay the onset of age-related diseases in everyone.

Link to paper: https://www.nature.com/articles/s41591-019-0343-4

Abstract.

Continue reading “The April Journal Club will be discussing the recent paper from the Salk Institute” »

Illustration of human embryonic stem cells. | Science Source/Ian Cuming.

We didn’t see that coming.

It turns out the capacity for offspring to benefit from their parents’ experiences doesn’t just happen with fish. Munday tells me about Daphnia, often called water fleas, that are found in freshwater lakes, ponds, and puddles. The tiny crustacean can hatch with either a round head or a pointed head. If it shares the water with predators such as fish or midges or other insects, spikes and spines help lessen the likelihood of being eaten. For many species of juvenile water flea…

Insights into epigenetics and inheritance show that some organisms can adapt to a changing world.

Researchers have tested nicotinamide mononucleotide on aged mice to see if it can help reverse age-related cognitive decline by improving blood flow in the brain.

The brain is a hungry organ

Healthy brain function relies on efficient cerebral blood flow (CBF) to wash away harmful waste products for disposal and supply the brain with an adequate supply of oxygen and sufficient nutrients.

Continue reading “NMN Improves Cognitive Function in Aged Mice” »

Some very good news.

Tesla plans to sell its solar panels at a price that’s 38 percent lower than the national average in an attempt to halt the decline of its solar business. The New York Times notes that the head of Tesla’s solar department, Sanjay Shah, wants to sell panels for between $1.75 and $1.99 a watt, compared to the national average of $2.85.

If they make it back, they’ll all be rich — but at what cost?